Overall rank by patents
#24,996
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Peter Maccallum Cancer Institute
USPTO PatentsView assignee record - 11 granted patents across 9 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
11
Total patents granted
9
CPC technology areas
11.1
Avg claims per patent
-43%
5-year filing velocity
The verdict
Peter holds 11 US patents across 9 technology areas, rank #24,996 of 50,000 tracked assignees.
- #24,996
- of 50,000 US assignees by volume
- Top 22%
- by Innovation Score (45.8/100)
- 11.1
- avg claims per patent
- -43%
- filing velocity, last 5 yrs
Portfolio overview
Peter Maccallum Cancer Institute has been granted 11 US utility patents between 2015 and 2025, placing Peter Maccallum Cancer Institute at rank #24,996 across all assignees tracked by PlainPatent. This portfolio spans 9 distinct Cooperative Patent Classification (CPC) subclasses, averaging 11.1 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Peter Maccallum Cancer Institute is one of the more focused assignees in the PatentsView dataset. By volume, Peter sits between Peptilogics, Inc. (11 patents, rank #24,992) and Phoenix Technologies Ltd. (11 patents, rank #25,000) - the closest US assignees by grant volume. The composite Innovation Score of 45.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 4 grants, compared with 7 in the 2015–2019 window, a -43% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Peter Maccallum Cancer Institute's 11.1 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 9 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Peter Maccallum Cancer Institute against peers pursuing similar technology classes.
Who files at Peter's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Peptilogics
Peptilogics, Inc.
11 patents
- Perceptimed
PerceptiMed, Inc.
11 patents
- Percutaneous Card…
Percutaneous Cardiovascular Solutions Pty Ltd
11 patents
- Pericom Semicondu…
Pericom Semiconductor Corporation
11 patents
- Phagenesis
Phagenesis Limited
11 patents
- Pham Holdings
Pham Holdings, Inc.
11 patents
- Philter Labs Inco…
Philter Labs Incorporated
11 patents
- Phoenix
Phoenix Technologies Ltd.
11 patents
- Peter Maccallum C… ◀
Peter MacCallum Cancer Institute
11 patents
What this shows Peter holds 11 patents at rank #24,996, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Peter's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
46 Top 22% higher than 78% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 9.1% |
| 2017 | 2 | 18.2% |
| 2018 | 4 | 36.4% |
| 2022 | 1 | 9.1% |
| 2023 | 1 | 9.1% |
| 2024 | 1 | 9.1% |
| 2025 | 1 | 9.1% |
Which technologies does Peter Maccallum Cancer Institute patent most?
Top 9 of 9 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Simple
Velocity Declining
Frequently Asked Questions
How many patents does Peter Maccallum Cancer Institute hold?
Peter Maccallum Cancer Institute holds 11 US granted patents filed between 2015 and 2025, spanning 9 technology areas.
What is Peter Maccallum Cancer Institute's Innovation Score?
Peter Maccallum Cancer Institute has an Innovation Score of 45.8 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Peter Maccallum Cancer Institute focus on?
Peter Maccallum Cancer Institute's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 8 patents. The company has filed patents in 9 CPC subclasses total.
Is Peter Maccallum Cancer Institute's patent filing rate increasing or decreasing?
Peter Maccallum Cancer Institute's recent filing velocity is -43% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Peter Maccallum Cancer Institute's patents?
Peter Maccallum Cancer Institute's patents average 11.1 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the Peter Maccallum Cancer Institute patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Peter's 11 grants land it in the top 22% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Peter ranks #24,996 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.